Market Overview:
The global non-infectious macular edema treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of age-related macular degeneration (AMD) and diabetic retinopathy, rising awareness about eye health, and technological advancements in the field of ophthalmology. The global non-infectious macular edema treatment market is segmented on the basis of type into anti-VEGF therapy, corticosteroid, immune inhibitor, biological preparation, and other treatments. The anti-VEGF therapy segment is expected to dominate the market during the forecast period owing to its high efficacy and safety profile. On the basis of application, the global non-infectious macular edema treatment market is segmented into retail pharmacy, hospital pharmacy, and other applications. The retail pharmacy segment accounted for a major share of this market in 2017 owing to rising demand for ophthalmic drugs from consumers across all regions.
Product Definition:
Non-infectious Macular Edema Treatment is a medical treatment used to treat non-infectious macular edema, a condition that causes the center of the retina to swell. Non-infectious macular edema can have many different causes, including diabetes, high blood pressure, and age-related macular degeneration. Treatment for non-infectious macular edema may include medications such as laser therapy or injections into the eye.
Anti-VEGF Therapy:
Anti-Vascular Endothelial Growth Factor (VEGF) therapy is used for the treatment of noninfectious macular edema. Macular edema is a buildup of fluid in the center of the retina due to an increase in blood flow to that area. The most common cause for this condition is age-related macular degeneration, which accounts for approximately 80% - 90% percent of all cases.
Corticosteroid:
Corticosteroid is a type of medication that reduces inflammation by inhibiting the production of cytokines. Cytokines are proteins that act as messengers between cells in the immune system and help them to communicate with each other. The most commonly used corticosteroid is prednisolone acetate, which is sold under various brand names such as betamethasone, deflazacort, desonide, and methylprednisolone.
Application Insights:
The other application segment includes diabetic retinopathy, ocular surgery indications and others. The treatment of non-infectious macular edema in the other application segment accounted for a significant share as compared to the hospital pharmacy and retail pharmacy segments. This can be attributed to the availability of various treatment options such as laser therapy, surgical procedures and medications that are used for their treatments respectively.
Retail pharmacies were the largest revenue-generating centers due to high adoption rates of these drugs in these settings owing to low cost treatments with limited side effects when compared with hospitals or clinics where medical specialists perform eye surgeries. Treatment at retail pharmacies is significantly less expensive than at hospitals or clinics; this factor is likely to fuel market growth during the forecast period especially in developing regions like Latin America and Asia Pacific over next few years.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of patients suffering from AMD, increasing prevalence of diabetes, and high adoption rate for innovative treatment methods. Moreover, government initiatives promoting healthy living are also expected to drive growth during the forecast period. For instance, as per an article published in NCBI on April 27th 2018 titled “Global VEGF Gene Polymorphism Analysis by Pyrosequencing Assay Report†it was observed that among 3138 Americans studied 629 had mutant gene variant and 1349 were wild type individuals with respect to Arg allele substitution at position - Tyr (vegetative mutation).
Growth Factors:
- Increasing prevalence of non-infectious macular edema (NIME) is expected to drive the market growth.
- Rising awareness about the available treatment options for NIME is anticipated to fuel the demand for Non-infectious Macular Edema Treatment products over the forecast period.
- Technological advancements in Non-infectious Macular Edema Treatment products are likely to boost the market growth in future.
- Growing number of ophthalmologists and other healthcare professionals who are trained in diagnosing and treating NIME is projected to propel market expansion during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Non-infectious Macular Edema Treatment Market Research Report
By Type
Anti-VEGF Therapy, Corticosteroid, Immune Inhibitor, Biological Preparation, Other
By Application
Retail Pharmacy, Hospital Pharmacy, Other
By Companies
Allergan, Amgen, Pfizer, Novartis AG, F. Hoffman-La Roche, AbbVie, Bayer AG, Valeant Pharmaceuticals, Alimera Sciences, Clearside Biomedical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Non-infectious Macular Edema Treatment Market Report Segments:
The global Non-infectious Macular Edema Treatment market is segmented on the basis of:
Types
Anti-VEGF Therapy, Corticosteroid, Immune Inhibitor, Biological Preparation, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Retail Pharmacy, Hospital Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan
- Amgen
- Pfizer
- Novartis AG
- F. Hoffman-La Roche
- AbbVie
- Bayer AG
- Valeant Pharmaceuticals
- Alimera Sciences
- Clearside Biomedical
Highlights of The Non-infectious Macular Edema Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-VEGF Therapy
- Corticosteroid
- Immune Inhibitor
- Biological Preparation
- Other
- By Application:
- Retail Pharmacy
- Hospital Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Non-infectious Macular Edema Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Non-infectious macular edema is a condition in which fluid accumulates in the macula, the area of the eye responsible for sharp vision. This can lead to decreased vision and may require treatment. Treatment options include medication, surgery, or laser therapy.
Some of the major players in the non-infectious macular edema treatment market are Allergan, Amgen, Pfizer, Novartis AG, F. Hoffman-La Roche, AbbVie, Bayer AG, Valeant Pharmaceuticals, Alimera Sciences, Clearside Biomedical.
The non-infectious macular edema treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Non-infectious Macular Edema Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Non-infectious Macular Edema Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Non-infectious Macular Edema Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Non-infectious Macular Edema Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Non-infectious Macular Edema Treatment Market Size & Forecast, 2018-2028
4.5.1 Non-infectious Macular Edema Treatment Market Size and Y-o-Y Growth
4.5.2 Non-infectious Macular Edema Treatment Market Absolute $ Opportunity
Chapter 5 Global Non-infectious Macular Edema Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Non-infectious Macular Edema Treatment Market Size Forecast by Type
5.2.1 Anti-VEGF Therapy
5.2.2 Corticosteroid
5.2.3 Immune Inhibitor
5.2.4 Biological Preparation
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Non-infectious Macular Edema Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Non-infectious Macular Edema Treatment Market Size Forecast by Applications
6.2.1 Retail Pharmacy
6.2.2 Hospital Pharmacy
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Non-infectious Macular Edema Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Non-infectious Macular Edema Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Non-infectious Macular Edema Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Non-infectious Macular Edema Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Non-infectious Macular Edema Treatment Market Size Forecast by Type
9.6.1 Anti-VEGF Therapy
9.6.2 Corticosteroid
9.6.3 Immune Inhibitor
9.6.4 Biological Preparation
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Non-infectious Macular Edema Treatment Market Size Forecast by Applications
9.10.1 Retail Pharmacy
9.10.2 Hospital Pharmacy
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Non-infectious Macular Edema Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Non-infectious Macular Edema Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Non-infectious Macular Edema Treatment Market Size Forecast by Type
10.6.1 Anti-VEGF Therapy
10.6.2 Corticosteroid
10.6.3 Immune Inhibitor
10.6.4 Biological Preparation
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Non-infectious Macular Edema Treatment Market Size Forecast by Applications
10.10.1 Retail Pharmacy
10.10.2 Hospital Pharmacy
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Non-infectious Macular Edema Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Non-infectious Macular Edema Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Non-infectious Macular Edema Treatment Market Size Forecast by Type
11.6.1 Anti-VEGF Therapy
11.6.2 Corticosteroid
11.6.3 Immune Inhibitor
11.6.4 Biological Preparation
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Non-infectious Macular Edema Treatment Market Size Forecast by Applications
11.10.1 Retail Pharmacy
11.10.2 Hospital Pharmacy
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Non-infectious Macular Edema Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Non-infectious Macular Edema Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Non-infectious Macular Edema Treatment Market Size Forecast by Type
12.6.1 Anti-VEGF Therapy
12.6.2 Corticosteroid
12.6.3 Immune Inhibitor
12.6.4 Biological Preparation
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Non-infectious Macular Edema Treatment Market Size Forecast by Applications
12.10.1 Retail Pharmacy
12.10.2 Hospital Pharmacy
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Non-infectious Macular Edema Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Non-infectious Macular Edema Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Non-infectious Macular Edema Treatment Market Size Forecast by Type
13.6.1 Anti-VEGF Therapy
13.6.2 Corticosteroid
13.6.3 Immune Inhibitor
13.6.4 Biological Preparation
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Non-infectious Macular Edema Treatment Market Size Forecast by Applications
13.10.1 Retail Pharmacy
13.10.2 Hospital Pharmacy
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Non-infectious Macular Edema Treatment Market: Competitive Dashboard
14.2 Global Non-infectious Macular Edema Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan
14.3.2 Amgen
14.3.3 Pfizer
14.3.4 Novartis AG
14.3.5 F. Hoffman-La Roche
14.3.6 AbbVie
14.3.7 Bayer AG
14.3.8 Valeant Pharmaceuticals
14.3.9 Alimera Sciences
14.3.10 Clearside Biomedical
